CN113645972A - 通过atp-竞争性akt抑制剂gdc-0068与e3连接酶配体的接合降解akt及使用方法 - Google Patents

通过atp-竞争性akt抑制剂gdc-0068与e3连接酶配体的接合降解akt及使用方法 Download PDF

Info

Publication number
CN113645972A
CN113645972A CN202080027366.1A CN202080027366A CN113645972A CN 113645972 A CN113645972 A CN 113645972A CN 202080027366 A CN202080027366 A CN 202080027366A CN 113645972 A CN113645972 A CN 113645972A
Authority
CN
China
Prior art keywords
compound
cancer
pharmaceutically acceptable
akt
methyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080027366.1A
Other languages
English (en)
Chinese (zh)
Inventor
N·格雷
I·尤
T·张
E·费希尔
K·多诺万
E·埃里克森
A·托克
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dana Farber Cancer Institute Inc
Beth Israel Deaconess Medical Center
Original Assignee
Dana Farber Cancer Institute Inc
Beth Israel Deaconess Medical Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dana Farber Cancer Institute Inc, Beth Israel Deaconess Medical Center filed Critical Dana Farber Cancer Institute Inc
Publication of CN113645972A publication Critical patent/CN113645972A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/545—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
CN202080027366.1A 2019-04-09 2020-04-08 通过atp-竞争性akt抑制剂gdc-0068与e3连接酶配体的接合降解akt及使用方法 Pending CN113645972A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962831267P 2019-04-09 2019-04-09
US62/831,267 2019-04-09
PCT/US2020/027236 WO2020210337A1 (en) 2019-04-09 2020-04-08 Degradation of akt by conjugation of atp-competitive akt inhibitor gdc-0068 with e3 ligase ligands and methods of use

Publications (1)

Publication Number Publication Date
CN113645972A true CN113645972A (zh) 2021-11-12

Family

ID=72750645

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080027366.1A Pending CN113645972A (zh) 2019-04-09 2020-04-08 通过atp-竞争性akt抑制剂gdc-0068与e3连接酶配体的接合降解akt及使用方法

Country Status (7)

Country Link
US (1) US12642857B2 (cg-RX-API-DMAC7.html)
EP (1) EP3952871A4 (cg-RX-API-DMAC7.html)
JP (1) JP7667742B2 (cg-RX-API-DMAC7.html)
CN (1) CN113645972A (cg-RX-API-DMAC7.html)
AU (1) AU2020270908B2 (cg-RX-API-DMAC7.html)
CA (1) CA3134491A1 (cg-RX-API-DMAC7.html)
WO (1) WO2020210337A1 (cg-RX-API-DMAC7.html)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024146599A1 (zh) * 2023-01-06 2024-07-11 南京正大天晴制药有限公司 一种二氢吡啶并[2,3-d]嘧啶酮的衍生物、其制备方法以及医药用途
WO2025124516A1 (zh) * 2023-12-14 2025-06-19 南京正大天晴制药有限公司 一种具有降解akt激酶活性的化合物及其制备方法和药学上的应用

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114478534B (zh) * 2020-10-24 2025-08-05 杭州中美华东制药有限公司 具有抗肿瘤活性的嵌合分子及其制备方法和应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017197055A1 (en) * 2016-05-10 2017-11-16 C4 Therapeutics, Inc. Heterocyclic degronimers for target protein degradation
WO2019173516A1 (en) * 2018-03-06 2019-09-12 Icahn School Of Medicine At Mount Sinai Serine threonine kinase (akt) degradation / disruption compounds and methods of use

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA95641C2 (xx) * 2006-07-06 2011-08-25 Эррей Биофарма Инк. Гідроксильовані піримідильні циклопентани як інгібітори акт протеїнкінази$гидроксилированные пиримидильные циклопентаны как ингибиторы акт протеинкиназы
EP4649963A3 (en) 2014-04-14 2026-05-13 Arvinas Operations, Inc. Imide-based modulators of proteolysis and associated methods of use
IL325256A (en) 2014-06-13 2026-02-01 Bach Biosciences Llc FAP-activated medical materials and related uses
WO2017185031A1 (en) 2016-04-22 2017-10-26 Dana-Farber Cancer Institute, Inc. Degradation of cyclin-dependent kinase 4/6 (cdk4/6) by conjugation of cdk4/6 inhibitors with e3 ligase ligand and methods of use

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017197055A1 (en) * 2016-05-10 2017-11-16 C4 Therapeutics, Inc. Heterocyclic degronimers for target protein degradation
CN109562107A (zh) * 2016-05-10 2019-04-02 C4医药公司 用于靶蛋白降解的杂环降解决定子体
WO2019173516A1 (en) * 2018-03-06 2019-09-12 Icahn School Of Medicine At Mount Sinai Serine threonine kinase (akt) degradation / disruption compounds and methods of use

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
PHILIPP OTTIS等: "Proteolysis-Targeting Chimeras: Induced Protein Degradation as a Therapeutic Strategy", 《ACS CHEMICAL BIOLOGY》, no. 12, pages 892 - 898 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024146599A1 (zh) * 2023-01-06 2024-07-11 南京正大天晴制药有限公司 一种二氢吡啶并[2,3-d]嘧啶酮的衍生物、其制备方法以及医药用途
WO2025124516A1 (zh) * 2023-12-14 2025-06-19 南京正大天晴制药有限公司 一种具有降解akt激酶活性的化合物及其制备方法和药学上的应用

Also Published As

Publication number Publication date
EP3952871A4 (en) 2023-06-07
US20220226481A1 (en) 2022-07-21
US12642857B2 (en) 2026-06-02
JP7667742B2 (ja) 2025-04-23
CA3134491A1 (en) 2020-10-15
AU2020270908A1 (en) 2021-09-16
AU2020270908B2 (en) 2025-09-25
WO2020210337A1 (en) 2020-10-15
JP2022526979A (ja) 2022-05-27
EP3952871A1 (en) 2022-02-16

Similar Documents

Publication Publication Date Title
CN116249683B (zh) 氘甲基取代吡嗪并吡嗪并喹啉酮类衍生物、其制备方法及其在医药上的应用
JP7709378B2 (ja) Heliosの低分子分解誘導剤および使用方法
EP4034132B1 (en) Erk5 degraders as therapeutics in cancer and inflammatory diseases
CN116514846A (zh) 杂环类衍生物、其制备方法及其医药上的用途
CN116157400B (zh) 杂环类衍生物及其制备方法和用途
CN112638380A (zh) 小脑蛋白(crbn)配体
US20230158157A1 (en) Potent and selective degraders of alk
CN113164475A (zh) Dyrk1a的大环抑制剂
JP7626721B2 (ja) 小分子標的ブロモ/アセチルタンパク質およびその使用
EP3813834A1 (en) New crbn modulators
CN116157401B (zh) 杂环类衍生物及其制备方法和用途
CN116113416B (zh) 四环类衍生物、其制备方法和其医药上的用途
CN117396208A (zh) 细胞周期蛋白依赖性激酶4/6(cdk4/6)和ikzf2(helios)的小分子降解剂及其使用方法
JP7667742B2 (ja) Atp競合性akt阻害剤gdc-0068とe3リガーゼリガンドとの結合によるaktの分解および使用方法
CN113747894B (zh) 成纤维细胞生长因子受体2(fgfr2)的降解剂
CN118695863A (zh) 靶向swi/snf相关的基质关联的肌动蛋白依赖性染色质调控因子亚家族a成员4(smarca4)
CN104876914B (zh) 嘧啶衍生物类间变性淋巴瘤激酶抑制剂
CN118119611A (zh) 用于降解dot1l的小分子及其用途
CN116801878A (zh) Her2的有效和选择性抑制剂
US12162876B2 (en) Indazole kinase inhibitor and use thereof
CN106146525A (zh) 三并环类间变性淋巴瘤激酶抑制剂
CN118772113A (zh) 作为DNA聚合酶Theta抑制剂的含氮杂环化合物
BR112019021703B1 (pt) Compostos heteroaromáticos, composição farmacêutica e uso destes

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
CB02 Change of applicant information

Country or region after: U.S.A.

Address after: Massachusetts, USA

Applicant after: Dana Faber Cancer Institute

Applicant after: BETH ISRAEL DEACONESS MEDICAL CENTER

Address before: Massachusetts, USA

Applicant before: DANA-FARBER CANCER INSTITUTE, Inc.

Country or region before: U.S.A.

Applicant before: BETH ISRAEL DEACONESS MEDICAL CENTER

CB02 Change of applicant information